SKYE

Skye Bioscience, Inc. is a biotechnology company focused on developing novel therapeutics aimed at improving metabolic health outcomes, particularly related to obesity and associated metabolic conditions. The company operates primarily in the early-stage biotech sector, advancing drug candidates through clinical proof-of-concept. Its key product is a peripheral CB1 inhibitor designed to address obesity and other metabolic diseases. Skye Bioscience engages with a range of life science investors and partners to support its research and development efforts, primarily targeting markets in the United States and Asia.